Indeed, preclinical studies showed decreased viability of CD34+CD38- cells and decreased colony-forming potential in AML primary samples, both of which suggest a selective reduction in the LSC compartment after niclosamide treatment [197]. This evidence concerns the gene CD38 and acute myeloid leukemia.